NOV 09, 2017 06:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Blood trails: nanotechnology-enabled biomarker quantification for early disease detection
Presented at the Clinical Diagnostics & Research 2017 Virtual Event
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: P.A.C.E. CE
1 1 7

Speakers:
  • Associate Professor, Biodesign Institute, Arizona State University
    Biography
      Tony Hu is an Associate Professor at the Biodesign Institute at Arizona State University's Virginia G. Piper Center for Personalized Diagnostics and at the Ira A. Fulton Schools of Engineering's School of Biological and Health Systems Engineering.

      Hu's research focuses on developing and validating integrated nanotechnique-based strategies for marker discovery and molecular diagnostics in peripheral blood samples to provide a translatable solution for personalized medicine. His innovations aim to fill current gaps in early detection, real-time therapy monitoring and effective prognostics. He has assembled a diverse team with backgrounds in biochemistry, mass spectrometry, nanofabrication, and biomedical engineering to answer these needs.

      Hu received his Ph.D. in Biomedical Engineering from the University of Texas at Austin where he focused on developing nanomaterials as biosensors for disease diagnosis. He has published more than 50 journal articles and has received five U.S. patents (issued and pending) on these subjects since his first faculty appointment in 2011. Hu has also published four nanomedicine-related book chapters, and has given more than 40 seminars and invited presentations at major international scientific conferences. His research team has a history of grants from the NCI, NIAID, NICHD and DOD and awards from the Gates, Dunn, Kostas, and Cockrell family foundations. His team has in-depth knowledge of multiplex-detection method development for sample processing, mass spectrometry, biomarker identification and validation. This background ideally positions his team for a leadership role in these fields and for optimal clinical translation of their platforms for improved and comprehensive analysis of blood-based biomarkers that have broad potential clinical applications.

    Abstract:

    Dr. Tony Hu’s research focuses on developing and validating integrated nanotechnique-based strategies for marker discovery and molecular diagnostics in peripheral blood samples to provide a translatable solution for personalized medicine. His innovations aim to fill current gaps in early detection, real-time therapy monitoring and effective prognostics. Instead of competing on lowering the detection limit of those known markers with poor specificity on disease diagnosis, Hu’s focus is to utilize nanotech-induced capabilities to discover those unknowns and to address major unsolved problems in oncology and infectious diseases.


    Show Resources
    Loading Comments...
    Show Resources
    Event Countdown
    • 0 Days
    • 0 Hours
    • 0 Minutes
    • 0 Seconds